FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washing

D.C. 20E40	
ton, D.C. 20549	
	│ OMB APPROVAL

OIVID ALL	TOVAL								
OMB Number:	3235-0287								
Estimated average burden									
hours nor roonones	. 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Arroyo Santiago					2. Issuer Name and Ticker or Trading Symbol Fulcrum Therapeutics, Inc. [FULC]							(Che	ck all application	able)	Person(s) to Iss 10% C Other		
(Last) (First) (Middle) C/O FULCRUM THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 11/07/2022							X Officer (give title Other (specify below) below) Chief Medical Officer					
26 LANDSDOWNE STREET				4.	If Amendment, Date of Original Filed (Month/Day/Year)							6. In	6. Individual or Joint/Group Filing (Check Applicable				
(Street)	IDGE M	1A	02139	_						Line	X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(5	State)	(Zip)														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			te	Execution Date,		Transaction Disposed Code (Instr.		ties Acquir d Of (D) (Ins	ed (A) or str. 3, 4 and 5	5. Amoun Securities Beneficia Owned Fo Reported	s F	6. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	v	Amount	Amount (A) or (D)		Transacti (Instr. 3 a			(111511.4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr.)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	11(3)		
Stock Option (right to buy)	\$5.61	11/07/2022		A		400,000		(1)	1	1/06/2032	Common Stock	400,000	\$0.00	400,000	D		

Explanation of Responses:

1. This option was granted on November 7, 2022 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of November 7, 2022. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.

Remarks:

/s/ Greg Tourangeau, as attorney-in-fact for Santiago <u>Arroyo</u>

11/09/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.